The Centre is expecting Zydus Cadila’s needle-free coronavirus vaccine ZyCoV-D to be available in early October, according to news agency ANI‘s report.
Indigenously developed Zydus Cadila’s ZyCoV-D last month received approval for Emergency Use Authorisation from the drug regulator, making it the first vaccine in India which would be administered in the age group of 12-18 years.
Covishield, Covaxin and Sputnik V vaccines are being given to only those above 18 years and unlike ZyCoV-D, which is three-dose, these are administered in two doses.
The Department of Biotechnology (DBT) had earlier said that ZyCoV-D is the world’s first DNA-based vaccine against Covid-19 and when injected produces the spike protein of the SARS-CoV-2 virus and elicits an immune response, which plays a vital role in protection from the disease as well as viral clearance.
It said that interim results from Phase-III clinical trials in over 28,000 volunteers showed primary efficacy of 66.6 per cent for symptomatic RT-PCR positive cases. This has been the largest vaccine trial so far in India for COVID-19, the DBT said.
The Covid-19 vaccine had already exhibited robust immunogenicity and tolerability and safety profile in the adaptive phase one and two clinical trials. Both Phase one/two and Phase three clinical trials have been monitored by an independent data safety monitoring board, the DBT added.
Explore the profound effects of excessive screen time on your child’s behavior and development. Discover…
Discover how simple daily changes in your diet and lifestyle can significantly improve your heart…
This article explores the common misconception that brain tumours primarily affect older adults, revealing the…
The first-ever ovarian cancer vaccine is poised to change the landscape of women's health by…
As dengue and chikungunya cases rise in Delhi during the monsoon season, understanding prevention strategies…
Skincare is a significant concern for women (and increasingly, men), with the quest for perfect,…